Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Foundation for Biomedical Research and Innovation Ties Up with Quintiles
February 5, 2001
- Korosho Holds 1st Explanatory Meeting for Prefectural Governmental Officials -1-
February 5, 2001
- Issues on PMS Discussed at JSWP Forum
February 5, 2001
- Total Abolishment of Financial Contribution to Elderly Healthcare Unrealistic: Korosho Senior Vice Minister
February 5, 2001
- JUSCO Ties Up with Welpark
February 5, 2001
- NDA Review Process Needs Further Improvement: New PMSB Director General
February 5, 2001
- Tsuruha to Enter Central Tokyo Market
February 5, 2001
- Council on Drugs and Food Sanitation Holds First Meeting
February 5, 2001
- Kobayashi Pharm Acquires Whitehall Japan Corp.
February 5, 2001
- JMA, Kemporen Leaders Agree on Need to Exchange Opinions in April
February 5, 2001
- OTC NEWS IN BRIES
February 5, 2001
- REGULATORY NEWS IN BRIEF
February 5, 2001
- GE-Yokogawa Medical Systems Focuses on Cardiovascular Devices
February 5, 2001
- More Than 80% of Clinics Selected Fixed Sum Copayment: PJ Survey
February 5, 2001
- Boston Scientific Japan: New Balloon Catheters for PTCA
February 5, 2001
- 80.7% of Clinics Select Fixed Sum Copayment
February 5, 2001
- MEDICAL DEVICE NEWS IN BRIEF
February 5, 2001
- Council to Study Ways to Supply Drug Information to Public
January 29, 2001
- Jovi to Increase Its Member Stores to 3,000
January 29, 2001
- REGULATORY NEWS IN BRIEF
January 29, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…